Finger-Based Blood Pressure Tracking | Mark Khachaturian, Wellvii | MTW North America 2026

Why It Matters

By making blood‑pressure measurement painless and reimbursable, Welvie’s finger‑cuff could dramatically raise patient adherence, lower cardiovascular events, and create a data‑rich platform for next‑generation digital health services.

Key Takeaways

• Finger‑cuff device replaces painful arm cuff, boosting compliance.
• FDA cleared algorithm; device clearance pending, targeting 2024 launch.
• Reimbursement via Medicare remote monitoring CPT codes drives adoption.
• $125 price point aims at home market, scaling to 1 million units.
• Platform plans include EKG, AI analytics, global HIPAA/GDPR compliance.

Summary

At MedTech World in Miami, Welvie CEO Mark Khachaturian unveiled a finger‑cuff blood‑pressure monitor designed to replace the century‑old arm cuff. The device captures arterial pressure from the fingertip, offering a painless, portable, rechargeable solution aimed at improving the roughly 35 % compliance rate in the United States.

Khachaturian explained that the finger‑cuff provides clinically accurate readings without the daily calibration required by optical wrist devices. The algorithm received FDA clearance in 2024, with the hardware expected to be cleared next month. Medicare’s 2019 remote‑monitoring reimbursement of $1,500 per patient per year under CPT codes creates a clear financial incentive for both patients and providers.

He highlighted a $125 consumer price, one‑million pre‑orders, and a goal to displace the 80 million arm cuffs sold globally. Integration uses Bluetooth and a cellular chip to stream data to a cloud‑based Azure platform, compliant with HIPAA and GDPR, and the company already runs pilots in the U.S., Asia and Europe.

The launch could accelerate home‑based hypertension management, generate massive real‑world data for AI‑driven analytics, and lay the groundwork for a modular platform that adds EKG and other vitals. Global scaling and reimbursement alignment position Welvie to reshape remote patient monitoring and reduce cardiovascular risk at scale.

Original Description

Mark Khachaturian, CEO of Wellvii, joins Logan Plaster in the Media Lounge at MedTech World North America 2026 to discuss the company’s FDA-cleared blood pressure monitoring technology and its vision for improving hypertension management through easier, more accessible patient monitoring.

Designed to measure blood pressure from the finger rather than the traditional arm cuff, Wellvii’s technology aims to improve patient compliance while supporting the growing demand for remote patient monitoring and connected healthcare solutions.

In this interview, Mark discusses:

• The challenges of traditional blood pressure monitoring

• The science behind finger-based blood pressure measurement

• The impact of remote patient monitoring reimbursement programs

• Integrating connected devices into healthcare workflows

• The role of cellular connectivity and cloud-based data management

• Expanding access to cardiovascular monitoring worldwide

• Future plans including EKG integration and AI-powered analytics

Recorded at MedTech World North America, held at the Hilton West Palm Beach, Florida, from 11–13 May 2026.

Subscribe for more conversations with MedTech founders, healthcare leaders, investors, and innovators from around the world.

#MedTechWorld #MedTechWorldNorthAmerica2026 #MedTech #Hypertension #BloodPressureMonitoring #RemotePatientMonitoring #DigitalHealth #MedicalDevices #HealthcareInnovation #CardiovascularHealth #ConnectedCare #ArtificialIntelligence #HealthTech #Wellvii #WestPalmBeach #MTWNorthAmerica "